Here are four notes:
1. The company’s underlying revenue increased by 3.8 percent year-to-year, led by strong performance in the U.S. and the emerging markets
2. It also reported an underlying core earnings increase of 1.5 percent year-to-year.
3. Underlying revenue from the gastroenterology market was up by 24.7 percent year-to-year.
4. Based on performance through three quarters, Takeda raised the full-year reported forecast for operating profit to 120 billion yen.
More articles on GI/endoscopy:
DuPage Medical Group acquires Midwest Digestive Disease Specialists: 3 things to know
8 must-reads on colonoscopy
5 things to know about office visit costs prior to screening colonoscopy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
